四款重磅大单品即将上市，创新驱动艾美疫苗估值向上

格隆汇2025-08-27

国内疫苗头部企业艾美疫苗(06660.HK)8月27日发布2025年上半年业绩，公司营收稳健，随着重磅大单品进入上市阶段，研发费用降低，经营开支优化。四款重磅大单品上市倒计时，即将步入商业化：迭代无血清狂犬疫苗上市注册申请已获受理；13价肺炎结合疫苗已申请上市注册，已完成现场核查；23价肺炎多糖疫苗已完成III期临床血清检测，即将进入统计揭盲工作；迭代工艺高效价人二倍体狂犬疫苗目前处于III期临床...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2562742914?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-27 21:57","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2562742914","market":"hk","top_or_hot":-1,"title":"四款重磅大单品即将上市，创新驱动艾美疫苗估值向上","media":"格隆汇","content":"<div>\n<p>国内疫苗头部企业艾美疫苗(06660.HK)8月27日发布2025年上半年业绩，公司营收稳健，随着重磅大单品进入上市阶段，研发费用降低，经营开支优化。四款重磅大单品上市倒计时，即将步入商业化：迭代无血清狂犬疫苗上市注册申请已获受理；13价肺炎结合疫苗已申请上市注册，已完成现场核查；23价肺炎多糖疫苗已完成III期临床血清检测，即将进入统计揭盲工作；迭代工艺高效价人二倍体狂犬疫苗目前处于III期临床...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n","source":"live_gelonghui","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>四款重磅大单品即将上市，创新驱动艾美疫苗估值向上</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n四款重磅大单品即将上市，创新驱动艾美疫苗估值向上\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-27 21:57 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/rss/live/live.xml><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>国内疫苗头部企业艾美疫苗(06660.HK)8月27日发布2025年上半年业绩，公司营收稳健，随着重磅大单品进入上市阶段，研发费用降低，经营开支优化。四款重磅大单品上市倒计时，即将步入商业化：迭代无血清狂犬疫苗上市注册申请已获受理；13价肺炎结合疫苗已申请上市注册，已完成现场核查；23价肺炎多糖疫苗已完成III期临床血清检测，即将进入统计揭盲工作；迭代工艺高效价人二倍体狂犬疫苗目前处于III期临床...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014302.SGD","symbol_name":"RHB Singapore Income Fund SGD","start_time":0,"source_url":"https://www.gelonghui.com/rss/live/live.xml","article_id":"2562742914","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562742914","pubTimestamp":1756303023,"columns":[],"sourceInfo":{"source_id":"live_gelonghui","name":"格隆汇"},"weMediaInfo":null,"summary":"国内疫苗头部企业艾美疫苗(06660.HK)8月27日发布2025年上半年业绩，公司营收稳健，随着重磅大单品进入上市阶段，研发费用降低，经营开支优化。四款重磅大单品上市倒计时，即将步入商业化：迭代无血","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159646":"疫苗","SG9999014302.SGD":"RHB Singapore Income Fund SGD","SG9999013486.USD":"LIONGLOBAL SINGAPORE DIVIDEND EQUITY (USD) INC A","LU0577902298.EUR":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (EUR) ACC","D05.SI":"星展集团控股","LU0188438112.USD":"SCHRODER ISF ASIAN EQUITY YIELD \"A\" ACC","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","SG9999013478.USD":"利安新加坡股息基金","LU0210637038.USD":"HSBC GIF THAI EQUITY \"AD\" INC","LU0672654166.SGD":"FTIF - Templeton Asian Growth A (acc) SGD-H1","SG9999002406.SGD":"利安新加坡信托基金","06660":"艾美疫苗","LU1956131251.USD":"BNP PARIBAS SUSTAINABLE ASIA EX-JAPAN EQUITY \"C\"MD (USD) INC","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU0878004406.USD":"UBS (LUX) KEY SELEC ASIA ALLOCATION OPPORTUNITY (USD) \"P\" (USD) INC","LU0878005551.USD":"UBS (LUX) KEY SELEC ASIA ALLOCATION OPPORTUNITY (USD) \"P\" (USD) ACC","SG9999002620.SGD":"LionGlobal South East Asia SGD","SGXZ24219693.SGD":"UNITED SG DYNAMIC INCOME FUND \"A\" (SGD) INC","LU0557290698.USD":"施罗德环球可持续增长基金","LU0543330483.HKD":"TEMPLETON ASIAN GROWTH \"A\" (HKD) ACC","DBS":"Invesco DB Silver Fund","LU0048597586.USD":"富达亚洲焦点A","LU0898667661.SGD":"JPMorgan Funds - Asia Pacific Income A (mth) SGD-H","LU0532188223.SGD":"JPMorgan Funds - ASEAN Equity A (acc) SGD","LU0261947096.USD":"FIDELITY FUNDS  SUSTAINABLE ASIA EQUITY \"A\" (USD) ACC","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","RJAW.SI":"DBS MB ePW240902","LU0205439572.USD":"富达亚太股息基金","SG9999016042.SGD":"Schroder Singapore Trust A Acc SGD","LU0192582467.USD":"SCHRODER ISF ASIAN EQUITY YIELD \"A\" (USD) INC MF","LU1504937902.USD":"CT (LUX) I ASIAN EQUITY INCOME \"DUP\" (EUR) INC","LU0823413587.USD":"BNP PARIBAS EMERGING EQUITY \"C\" (USD) ACC","LU0971096721.USD":"富达环球金融服务 A","LU1839390173.USD":"JPM ASEAN EQUITY \"A\" (USD) INC","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","LU0251143029.SGD":"Fidelity ASEAN A-SGD","LU0384037296.USD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AT\" (USD) ACC","LU1282649067.USD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AMG\" (USD) INC A","SGXZ58947870.SGD":"LIONGLOBAL SINGAPORE DIVIDEND EQUITY (SGDHDG) INC","SG9999014484.SGD":"Nikko AM ASEAN Equity Fund A SGD","BK4134":"信息科技咨询与其它服务","SG9999002414.USD":"LIONGLOBAL SINGAPORE TRUST (USD) ACC","III":"信息服务","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","LU0955623706.USD":"SCHRODER ISF ASIAN DIVIDEND MAX \"A\" (USD) ACC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0831103253.SGD":"JPMorgan Funds - Asia Pacific Income A (mth) SGD","LU0345775950.USD":"NINETY ONE GSF ASIAN EQUITY \"A\" (USD) ACC","LU0441854154.USD":"JPM ASIA PACIFIC EQUITY \"A\" (USD) ACC"},"translate_title":"Four blockbuster single products are about to be launched, and innovation drives the valuation of Emmy vaccine to rise","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"DBS":1,"III":1,"RJAW.SI":1,"D05.SI":1,"06660":1},"content_text":"国内疫苗头部企业艾美疫苗(06660.HK)8月27日发布2025年上半年业绩，公司营收稳健，随着重磅大单品进入上市阶段，研发费用降低，经营开支优化。四款重磅大单品上市倒计时，即将步入商业化：迭代无血清狂犬疫苗上市注册申请已获受理；13价肺炎结合疫苗已申请上市注册，已完成现场核查；23价肺炎多糖疫苗已完成III期临床血清检测，即将进入统计揭盲工作；迭代工艺高效价人二倍体狂犬疫苗目前处于III期临床阶段，预计2026年提交上市注册申请。\n目前，艾美拥有针对12种疾病领域的20款在研疫苗产品，拥有23个临床批件 ，开展了24项临床试验，1类创新型疫苗7款。其中，三款1类创新型疫苗已获批开展临床 ：EV71-CA16二价手足口病灭活疫苗 （人二倍体细胞）已获批开展I期临床 ；mRNA带状疱疹疫苗 、mRNA呼吸道合胞病毒疫苗，均同时获批中美两国开展临床试验。出海业务方面，四价流脑多糖疫苗顺利进入非洲市场，并在中亚地区开展注册；狂犬疫苗首次进入中美洲市场；乙肝疫苗在东南亚积极开展注册流程，甲肝疫苗顺利推进南亚地区注册。\n凭借大单品商业化在即，创新技术的突破性进展，星展银行(DBS Bank)此前发布的研究报告认为：艾美疫苗有望在2026年实现盈利，且2025至2027年公司销售额预计以45%的年均复合增长率快速增长。业绩拐点将推动公司股价重估，估算的公允价值为8.3港元/股，意味着相较当下有近60%的上涨空间。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2562742914","isCrawlerRequest":true}